Determining the minimal important difference of EQ-5D-5 L utility values in CIDP patients using data from a large clinical trial.
Febe Brackx, Clémence Arvin-Berod, Glenn Phillips et al.
✦ AI-curated · Sources linked
In 30 seconds
This analysis of data from the ADHERE randomized controlled trial estimated the minimal important difference (MID) in EQ-5D-5 L utility values for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Using patient-reported change, disability scores, regression, receiver-operating-characteristic analysis and a distribution-based method, estimates ranged from 0.10 to 0.14; the Patient Global Impression of Change (PGIC)-based estimate was 0.11. In the open-label extension, 66.5% of patients achieved this threshold by week 12 (n = 188). The authors propose 0.11 as a useful threshold for interpreting utility changes in CIDP.
Key findings
- MID estimates ranged from 0.10 (regression and ROC) to 0.14 (a 1-point aINCAT decrease and distribution-based estimate).
- The PGIC-based MID was 0.11 for patients reporting they were “a little better.”
- In the open-label extension, 66.5% of patients achieved the MID by week 12 (n = 188).
Why it matters
A condition-specific MID can help clinicians and researchers judge whether changes in EQ-5D-5 L utility scores are meaningful to patients with CIDP, rather than merely measurable. The estimates also provide a reference for interpreting quality-of-life outcomes in future evaluations, with the PGIC-based value reflecting patients’ perceived improvement.
What to keep in mind
The MID estimates depend on the chosen anchor or statistical method, and the open-label extension result does not provide a randomized comparison.